[Neurology].

Area of Science:

• Neurology
• Immunology
• Genetics
• Pharmacology

Background:

• Advances in treating neurological conditions are rapidly evolving.
• Targeted therapies and revised diagnostic criteria are improving patient outcomes.
• Multiple sclerosis, myasthenia gravis, and amyloidosis represent significant challenges in neuro-immunology and genetics.

Purpose of the Study:

• To review recent advancements in the treatment of multiple sclerosis, myasthenia gravis, and transthyretin familial amyloidosis.
• To highlight emerging non-pharmacological approaches for headache and migraine management.
• To note revisions in diagnostic criteria for Lewy body dementia and the safety of generic lamotrigine.

Main Methods:

• Review of approved therapies including monoclonal antibodies and gene therapy.
• Discussion of non-pharmacological interventions for migraines.
• Summary of updated diagnostic criteria for Lewy body dementia.
• Analysis of safety data for generic lamotrigine.

Main Results:

• Ocrelizumab (anti-CD20) is approved for multiple sclerosis.
• Eculizumab (Soliris) is approved for severe generalized myasthenia gravis.
• Patisiran gene therapy shows positive results in transthyretin familial amyloidosis.
• Non-pharmacological migraine treatments show promise.
• Revised criteria for Lewy body dementia are available.
• Generic lamotrigine use is safe regarding seizures and adverse effects.

Conclusions:

• Significant progress has been made in targeted therapies for neurological and neuromuscular disorders.
• Diverse treatment modalities, from immunotherapy to gene therapy and non-pharmacological approaches, are expanding therapeutic options.
• Updated diagnostic criteria and safety profiles of generic medications contribute to better patient management.